Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Gabapentin; gamma-Aminobutyric Acid

Criteria

Inclusion Criteria:

1. 18 years of age or older

2. Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)

3. Have symptomatic headache

4. Able to swallow and verbalize pain score

5. No known allergy to gabapentin or fentanyl

6. Numeric pain score ≥ 5

7. Ability to provide written personal consent

Exclusion Criteria:

1. Gabapentin use prior to SAH admission

2. Renal failure with creatinine clearance less than 30 mL/min

3. Unable to receive standard of care pain medications

4. Pregnant or breastfeeding patients

5. History of severe depression defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV)